Literature DB >> 23287772

Efficacy of FDG-PET for defining gross tumor volume of head and neck cancer.

Chikae Kajitani1, Isao Asakawa, Fumiaki Uto, Emiko Katayama, Kazuya Inoue, Tetsuro Tamamoto, Norihisa Shirone, Hideyuki Okamoto, Tadaaki Kirita, Masatoshi Hasegawa.   

Abstract

We analyzed the data for 53 patients with histologically proven primary squamous cell carcinoma of the head and neck treated with radiotherapy between February 2006 and August 2009. All patients underwent contrast-enhanced (CE)-CT and (18)F-fluorodeoxyglucose (FDG)-PET before radiation therapy planning (RTP) to define the gross tumor volume (GTV). The PET-based GTV (PET-GTV) for RTP was defined using both CE-CT images and FDG-PET images. The CE-CT tumor volume corresponding to a FDG-PET image was regarded as the PET-GTV. The CE-CT-based GTV (CT-GTV) for RTP was defined using CE-CT images alone. Additionally, CT-GTV delineation and PET-GTV delineation were performed by four radiation oncologists independently in 19 cases. All four oncologists did both methods. Of these, PET-GTV delineation was successfully performed in all 19 cases, but CT-GTV delineation was not performed in 4 cases. In the other 15 cases, the mean CT-GTV was larger than the PET-GTV in 10 cases, and the standard deviation of the CT-GTV was larger than that of the PET-GTV in 10 cases. Sensitivity of PET-GTV for identifying the primary tumor was 96%, but that of CT-GTV was 81% (P < 0.01). In patients with oropharyngeal cancer and tongue cancer, the sensitivity of CT-GTV was 63% and 71%, respectively. When both the primary lesions and the lymph nodes were evaluated for RTP, PET-GTV differed from CT-GTV in 19 cases (36%). These results suggested that FDG-PET is effective for defining GTV in RTP for squamous cell carcinoma of the head and neck, and PET-GTV evaluated by both CE-CT and FDG-PET images is preferable to CT-GTV by CE-CT alone.

Entities:  

Keywords:  FDG-PET; gross tumor volume; head and neck cancer; target delineation

Mesh:

Substances:

Year:  2013        PMID: 23287772      PMCID: PMC3709660          DOI: 10.1093/jrr/rrs131

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


INTRODUCTION

Recent advances in radiation oncology and technology, such as 3D-conformal radiotherapy (3D-CRT) and intensity-modulated radiation therapy (IMRT), have improved the dose conformality of radiation treatment planning (RTP). Especially in the head and neck area, highly conformal RTP is very useful for escalating the tumor dose without increasing normal tissue injury, and precise identification of the target volume in RTP is essential. Most common RTP has been performed using anatomical images from CT scanning or MRI. Functional or biological imaging by positron emission tomography (PET) is expected to provide more useful information than anatomical imaging alone so that more appropriate RTP can be performed [1, 2]. 18F-fluorodeoxyglucose (FDG)-PET has recently been used to verify the target volume in RTP for various malignancies, especially non-small-cell lung cancer, head and neck cancer, etc. [3-6]; however, it has not been well established how FDG-PET can be utilized for actual treatment planning for many different types of malignancies, and various approaches for the suitable use of PET for RTP have been suggested. In the present study, we evaluated the efficacy of FDG-PET for defining the gross tumor volume (GTV) of head and neck cancer to establish RTP using functional imaging.

MATERIALS AND METHODS

We analyzed the data for 53 patients with histologically proven primary squamous cell carcinoma of the head and neck treated with radiotherapy in Nara Medical University Hospital between February 2006 and August 2009. All patients underwent routine contrast-enhanced (CE)-CT and FDG-PET for staging and defining the GTV. PET images were acquired about 60 min after intravenous administration of 3 MBq/kg FDG. If FDG-PET could not be performed before RTP, patients were excluded from this study. Plain CT simulation for RTP of patients in the supine position, immobilized with a head-rest and thermoplastic mask, was also performed. RTP of the head and neck cancer was performed based on CT simulation using both CE-CT and FDG-PET images with a visual method [5, 7], according to the institute definition of the target volume for PET-based RTP. The definition is as follows: CE-CT-based GTV (CT-GTV) for RTP is defined using conventional CE-CT images alone. PET-based GTV (PET-GTV) for RTP is defined using both CE-CT and FDG-PET images. The CE-CT volume corresponding to a positive FDG-PET image was regarded as the PET-GTV, and RTP was performed using the GTV, with inflammatory FDG accumulation being excluded by a nuclear radiologist. If PET images were regarded as inappropriate for RTP due to false-positive or false-negative, CT-GTV was used predominantly for RTP. In the present study, PET-GTV was compared with CT-GTV to evaluate the importance of FDG-PET information on target definition in RTP. The sensitivity of CE-CT alone for identifying primary lesions, and that of the combination of CE-CT and FDG-PET was calculated, comparing the histologically proven lesions as the standard of reference; however, the specificity was not assessed because of the bias of the patients in this study, i.e. exclusively patients with histologically proven squamous cell carcinoma of the head and neck. Statistical significance of the difference in sensitivity was assessed by the McNemer test (StatMate IV for Windows V4.01; ATMS, Tokyo). The PET-GTV for each case was then compared with the CT-GTV in order to evaluate the importance of the FDG-PET information in identifying lymph node metastases for RTP. However, the sensitivity and the specificity of PET-GTV and CT-GTV were not assessed for lymph nodes, because most of the lymph nodes had not been histologically studied in these cases, although every primary squamous cell carcinoma was histologically confirmed. In addition to the above study, CT-GTV delineation and PET-GTV delineation in 19 cases (13 patients with tongue cancer and 6 patients with oropharyngeal cancer) were performed by four radiation oncologists independently to evaluate the difference in volume due to interobserver variability in the GTV delineation. The statistical significance of the difference in GTV was assessed by the Wilcoxon signed-ranks test (StatMate IV for Windows V4.01; ATMS, Tokyo).

RESULTS

Patient characteristics for the 53 cases are shown in Table 1. Of the 53 primary tumor sites, 51 lesions showed positive accumulation of FDG; the sensitivity of PET-GTV for identifying the primary site was 96% (Table 2 and Figures 1–5). The margins of the tumors on PET and PET/CT images were relatively ill-defined and not always clear. The PET-GTV was smaller in some cases and larger in other cases than the CT-GTV. In two cases (tongue cancer and gingiva cancer), it was difficult to determine the GTV by PET (Table 2 and Fig. 4).
Table 1.

Patient characteristics

CharacteristicsNumber of patients
Gender
 Male39
 Female14
Stage
I0
II13
III13
IVA27
IVB0
Tumor site
 Oral cavity31
  tongue14
  gingiva8
  buccal mucosa4
  mouth floor4
  others1
 Pharynx13
  oropharynx8
  hypopharynx5
 Nasal cavity/Paranasal sinus7
 Others2
Total53
Table 2.

Sensitivity (%) of CT-GTV and PET-GTV for identifying primary tumors

CT-GTVSensitivityPET-GTVSensitivity
npositive%positive%
Oral cavity3124772994
 tongue1410711393
 gingiva8675788
 bucca441004100
 mouth floor441004100
 others1001100
Pharynx13107713100
 oropharynx85638100
 hypopharynx551005100
Nasal/Para771007100
Others221002100
Total5343815196

Nasal/Para = Nasal cavity/Paranasal sinus

Fig. 1.

A case of squamous cell carcinoma of the tongue. The primary tumor lesion was not evident on plain CT (a) and CE-CT (d-f) images due to artifacts induced by artificial teeth, but the lesion was evident on FDG-PET (b) and FDG-PET/CT (c) images (arrows).

Fig. 4.

A case of squamous cell carcinoma of the gingiva. The primary tumor lesion was not evident on plain CT (a) and CE-CT (d–f) images due to artifacts induced by artificial teeth. FDG-PET (b) and FDG-PET/CT (c) images showed positive FDG accumulation (arrows), but it was difficult to determine the GTV because the accumulation was not specific to the tumor.

A case of squamous cell carcinoma of the tongue. The primary tumor lesion was not evident on plain CT (a) and CE-CT (d-f) images due to artifacts induced by artificial teeth, but the lesion was evident on FDG-PET (b) and FDG-PET/CT (c) images (arrows). A case of squamous cell carcinoma of the gingiva. The primary tumor lesion was not evident on plain CT (a) and CE-CT (d–f) images due to artifacts induced by artificial teeth. FDG-PET (b) and FDG-PET/CT (c) images showed positive FDG accumulation (arrows), but it was difficult to determine the GTV because the accumulation was not specific to the tumor. Patient characteristics Sensitivity (%) of CT-GTV and PET-GTV for identifying primary tumors Nasal/Para = Nasal cavity/Paranasal sinus In contrast, the GTV of 10 cases was not clear (that of 43 cases was evident) on CE-CT images; the sensitivity of CT-GTV for identifying the primary tumor site was 81% (Table 2) and was significantly lower than that of PET-GTV (P < 0.01). In 43 cases, no significant difference was found between PET-GTV and CT-GTV when they were compared to identify the localization of the primary lesions. In 14 patients with tongue cancer, 10 tumors were evident on CE-CT images, but 4 primary lesions were not clear and 3 of these were due to artifacts induced by bones, teeth, or artificial teeth; sensitivity of CT-GTV to a primary site on the tongue was 71% and that of PET-GTV was 93% (Table 2, Figures 1 and 2). In 8 patients with gingival cancer, 6 tumors were evident, but 2 primary lesions were not clear due to artifacts; sensitivity of CT-GTV to the primary site was 75% and that of PET-GTV was 88% (Table 2, Figures 3 and 4). In 8 patients with oropharyngeal cancer, 3 primary lesions were not obvious; sensitivity of CT-GTV to the primary site was 63% and that of PET-GTV was 100% (Table 2 and Fig. 5).
Fig. 2.

A case of squamous cell carcinoma of the tongue. The primary tumor lesion was not evident on plain CT (a) and CE-CT (d–f) images regardless of slight artifact, but the lesion was evident on FDG-PET (b) and FDG-PET/CT (c) images (arrows).

Fig. 3.

A case of squamous cell carcinoma of the gingiva. The primary tumor lesion was not evident on plain CT (a) and CE-CT (d–f) images due to artifacts induced by artificial teeth, but the lesion was evident on FDG-PET (b) and FDG-PET/CT (c) images (arrows).

Fig. 5.

A case of squamous cell carcinoma of the oropharynx. The primary tumor lesion on plain CT (a) and CE-CT (d–f) images was not as obvious as on FDG-PET (b) and FDG-PET/CT (c) images (arrows).

A case of squamous cell carcinoma of the tongue. The primary tumor lesion was not evident on plain CT (a) and CE-CT (d–f) images regardless of slight artifact, but the lesion was evident on FDG-PET (b) and FDG-PET/CT (c) images (arrows). A case of squamous cell carcinoma of the gingiva. The primary tumor lesion was not evident on plain CT (a) and CE-CT (d–f) images due to artifacts induced by artificial teeth, but the lesion was evident on FDG-PET (b) and FDG-PET/CT (c) images (arrows). A case of squamous cell carcinoma of the oropharynx. The primary tumor lesion on plain CT (a) and CE-CT (d–f) images was not as obvious as on FDG-PET (b) and FDG-PET/CT (c) images (arrows). Lymph node metastases were suggested in 41 cases (77%) by CE-CT and in 32 cases (60%) by FDG-PET. Neither CE-CT nor FDG-PET showed evident metastases in 11 cases (21%). The PET-GTV differed from the CT-GTV in 11 cases (21%) when we evaluated lymph nodes for RTP. Swollen but FDG-negative lymph nodes were not regarded as the PET-GTV according to the definition of the target volume for PET-based RTP. In 10 cases (19%), lymph nodes were regarded as the CT-GTV but they were FDG-negative. In contrast, in only one case, lymph nodes were not swollen significantly, but showed evident accumulation of FDG. When both the primary lesions and the lymph nodes were evaluated for RTP, the PET-GTV differed from the CT-GTV in primary lesions, lymph nodes, or both in 19 cases (36%) and no significant difference was found between the PET-GTV and the CT-GTV in the other 34 cases (64%). In comparison of the CT-GTV and the PET-GTV as delineated by 4 radiation oncologists, PET-GTV delineation was successfully performed in all 19 cases, but CT-GTV delineation was not performed in 4 cases by any radiation oncologists due to unclear tumor images (Fig. 6). We evaluated the differences in the CT-GTV and the PET-GTV in the other 15 cases. The CT-GTV was larger than the PET-GTV in 10 of 15 cases, but the difference was not significant (P = 0.12). The standard deviation (SD) for the CT-GTV was larger than that for the PET-GTV in 10 cases, and the difference was statistically significant (P < 0.01).
Fig. 6.

Comparison of gross tumor volume (GTV) delineated by four radiation oncologists (mean + standard deviation): It was difficult to delineate CT-GTV in four cases (No. 3, 4, 6 and 14). In the other 15 cases, the mean CT-GTV was larger than PET-GTV in 10 cases, and the standard deviation of CT-GTV was larger than that of PET-GTV in 10 cases.

Comparison of gross tumor volume (GTV) delineated by four radiation oncologists (mean + standard deviation): It was difficult to delineate CT-GTV in four cases (No. 3, 4, 6 and 14). In the other 15 cases, the mean CT-GTV was larger than PET-GTV in 10 cases, and the standard deviation of CT-GTV was larger than that of PET-GTV in 10 cases.

DISCUSSION

FDG-PET has been used as a very useful imaging modality for detecting malignant primary lesions and lymph node metastases. Very high sensitivity of the primary lesions, and the high sensitivity and specificity of lymph node metastases of the head and neck have often been reported [8-10]. RTP using FDG-PET has recently been performed in anticipation of more appropriate target planning [5, 6]. Many studies of lung cancer and head and neck cancer have been reported during the past decade [5–7, 10–17]; however, the efficacy of FDG-PET for RTP for various malignancies has not been well established [18]. Recently, Troost et al. [19] concluded that PET can characterize tumors for radiotherapy, which is a promising prospect, but unresolved issues remain and the applications are not yet ready for introduction into routine clinical practice. Schinagl et al. [20] suggested that FDG-PET may be important for GTV definition, but the choice of a segmentation tool for target-volume definition based on PET images is not trivial and the absolute PET volume is dependent on the segmentation method. Several different threshold techniques for delineating tumors on PET have been used, and the choice of technique leads to large differences in target volume [5, 10]. In our institute, RTP is performed based on CT simulation using both CE-CT and FDG-PET or FDG-PET/CT images with a visual method [5, 7], and fusion of FDG-PET images and CT simulation is not performed. The institute definition of the target volume for PET-based RTP has been used for the past five years. PET-based GTV for RTP is defined using both CE-CT and FDG-PET images. When PET images are regarded as inappropriate for RTP due to false negatives or false positives, the GTV for RTP are determined using CE-CT images predominantly. The present study has shown the utility of FDG-PET for RTP of head and neck cancer in patients with histologically proven squamous cell carcinoma. The addition of FDG-PET image information to the CE-CT image resulted in significant changes to the GTV for RTP in 19 cases (36%). The sensitivity of PET-GTV for the 53 primary tumor sites was 96%; however, that of CT-GTV was 81%; in patients with oropharyngeal cancer and those with tongue cancer, the sensitivity of CT-GTV was no more than 63% and 71% respectively, due to false negatives for artifacts, etc. Changes in the GTV using FDG-PET have been reported in several studies of head and neck cancer [5, 11–13], varying from 11% to 93%, and the PET-GTV was smaller in some cases and larger in other cases than the CT-GTV. These results suggest that the additional use of FDG-PET is more effective for RTP than CE-CT alone and this will be recommended for defining the GTV for RT; however, the specificity for the identification of lesions could not be evaluated in this study because the cases were limited to patients with histologically proven cancer who had been referred to the Department of Radiation Oncology for RT. Target delineation, or automated tumor contouring for RTP by FDG-PET, has often been demonstrated [5, 6, 10], but tumor contouring by PET was outside the scope of the present study. Target delineation for RTP by defining the percentage of the maximum standardized uptake value (SUV) of FDG has been reported [12, 13, 21]; however, this method may have limitations [22]. Tumor delineation using an SUV of 2.5 has been considered insufficient in other studies [20, 23]. Visual comparison of FDG-PET images and CT simulation [5, 7] was utilized in this study, and the visual correlation of FDG-PET and CT simulation yielded higher sensitivity for the identification of primary lesions of the head and neck cancer regardless of exact tumor contouring, as suggested above. It has often been indicated that interobserver variability in target volume delineation of both head and neck cancer and lung cancer is reduced by using PET [24-28]; however, Breen et al. [29] reported that the addition of PET-CT to primary site GTV delineation of head and neck cancer did not change the GTV defined by expert observers and CE-CT would be more reliable than PET-CT. The present study suggests that the interobserver difference in target delineation will be decreased by using FDG-PET due to its excellent ability to identify primary gross tumors of the head and neck.

CONCLUSION

In conclusion, the results of this study have shown that FDG-PET is effective for defining the GTV in RTP for squamous cell carcinoma of the head and neck, and the sensitivity of FDG-PET for defining the primary tumor is higher than that of CE-CT alone. PET-GTV evaluated by both CE-CT and FDG-PET images is indicated to be preferable to CT-GTV by CE-CT alone, but further studies will be necessary to establish the standard use of FDG-PET for RTP. In particular, it would be desirable to perform more accurate GTV delineation by using other methods different from those mentioned above.

FUNDING

This study was partially supported by a Grant-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japan (No. 22791216).
  28 in total

Review 1.  Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality.

Authors:  C C Ling; J Humm; S Larson; H Amols; Z Fuks; S Leibel; J A Koutcher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

2.  Molecular (functional) imaging for radiotherapy applications: an RTOG symposium.

Authors:  J D Chapman; Jeffrey D Bradley; Janet F Eary; Roland Haubner; S M Larson; Jeff Michael Michalski; Paul G Okunieff; H W Strauss; Y C Ung; Michael J Welch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-02-01       Impact factor: 7.038

3.  Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer.

Authors:  Arnold C Paulino; Mary Koshy; Rebecca Howell; David Schuster; Lawrence W Davis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

4.  Molecular imaging in radiotherapy planning for head and neck tumors.

Authors:  Vincent Grégoire; Arturo Chiti
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

Review 5.  PET and [18F]-FDG in oncology: a clinical update.

Authors:  P S Conti; D L Lilien; K Hawley; J Keppler; S T Grafton; J R Bading
Journal:  Nucl Med Biol       Date:  1996-08       Impact factor: 2.408

6.  Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging.

Authors:  Christopher Scarfone; William C Lavely; Anthony J Cmelak; Dominique Delbeke; William H Martin; Dean Billheimer; Dennis E Hallahan
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

7.  Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen.

Authors:  Jean-François Daisne; Thierry Duprez; Birgit Weynand; Max Lonneux; Marc Hamoir; Hervé Reychler; Vincent Grégoire
Journal:  Radiology       Date:  2004-08-18       Impact factor: 11.105

8.  Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas.

Authors:  Takeshi Nishioka; Tohru Shiga; Hiroki Shirato; Eriko Tsukamoto; Kazuhiko Tsuchiya; Takashi Kato; Keiichi Ohmori; Akira Yamazaki; Hidefumi Aoyama; Seiko Hashimoto; Ta-Chen Chang; Kazuo Miyasaka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-15       Impact factor: 7.038

9.  Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.

Authors:  Jeffrey Bradley; Wade L Thorstad; Sasa Mutic; Tom R Miller; Farrokh Dehdashti; Barry A Siegel; Walter Bosch; Rudi J Bertrand
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-05-01       Impact factor: 7.038

10.  Impact of combined (18)F-FDG PET/CT in head and neck tumours.

Authors:  R Syed; J B Bomanji; N Nagabhushan; S Hughes; I Kayani; A Groves; S Gacinovic; N Hydes; D Visvikis; C Copland; P J Ell
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

View more
  2 in total

1.  Gross tumour volume comparison in oropharynx carcinomas using different intelligent imaging software. A retrospective analysis.

Authors:  Sigmund Stuppner; Justyna Waskiewicz; Antonio Ruiu
Journal:  Pol J Radiol       Date:  2020-06-05

2.  Deep learning-based auto-delineation of gross tumour volumes and involved nodes in PET/CT images of head and neck cancer patients.

Authors:  Yngve Mardal Moe; Aurora Rosvoll Groendahl; Oliver Tomic; Einar Dale; Eirik Malinen; Cecilia Marie Futsaether
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-09       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.